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Background/aim: Insulin-like growth factor (IGF)-I is a differentiation and growth factor. Antifibrotic action of octreotide has been
reported in pulmonary fibrosis. The present study aimed to research the prophylactic and therapeutic potential of octreotide on a
bleomycin (BLM)-induced experimental scleroderma model.
Materials and methods: Sixty Balb/c female mice were divided into 6 groups. Daily subcutaneous BLM (100 µg) was injected for 3
weeks in groups II and III and for 6 weeks in groups V and VI. Octreotide (100 µg/kg per day) was injected subcutaneously for the first
3 weeks in group III (prophylactic) and the second 3 weeks in group VI (therapeutic). Mice in groups I, II, and III were sacrificed at the
end of the third week, while mice in groups IV, V, and VI were sacrificed at the end of the sixth week.
Results: Repeated BLM applications increased dermal inflammatory cell counts and dermal thickness, and led to dermal fibrosis at both
the third and sixth weeks. Moreover, mRNA expressions of TGF-β1 and IGF binding protein (IGFBP)-3 and -5 were higher in the BLMinjected sham groups. On the other hand, IGFBP-3 and -5 mRNA expressions were significantly decreased in both the prophylactic and
therapeutic octreotide groups. Similarly, octreotide decreased dermal inflammatory infiltrations and dermal thickness.
Conclusion: Octreotide has antifibrotic actions on experimentally induced dermal fibrosis. It can be suggested that IGF-I plays
pathogenic roles, and octreotide is a candidate for research in the treatment of scleroderma.
Key words: Scleroderma, dermal fibrosis, insulin-like growth factor-I, octreotide

1. Introduction
Systemic sclerosis (SSc) is a chronic inflammatory disease
characterized by widespread fibrosis of skin and several
visceral organs (1). The pathogenesis of SSc is not yet fully
understood; however, fibrosis, immune activation, and
vasculopathy are known to be the main determinants
of pathogenesis (2). Endothelial and inflammatory cells
activate the fibroblasts directly via cell–cell interactions or
indirectly via cytokines and growth factors (3,4). Activated
fibroblasts, also known as myofibroblasts, are the main actors
for the excessive production of extracellular matrix (ECM).
Myofibroblasts also produce profibrotic cytokines (interleukin
[IL]-6) and growth factors (TGF-β1, connective tissue growth
factor, and platelet-derived growth factor) (3,4). These
properties suggest the autonomy of the myofibroblasts in SSc.
It has been reported that the infiltration of inflammatory cells
in skin lesions decreases over time (5). Therefore, fibroblasts
and growth factors are responsible for sustained fibrosis.

Insulin-like growth factor (IGF)-I is a growth and
differentiation factor (6,7). Rothe et al. (8) have reported
increased serum IGF-I level in SSc patients. Moreover,
increased IGF-I level has been demonstrated in
bronchoalveolar fluids of SSc patients with pulmonary
fibrosis (9). Serum and dermal tissue IGF-I levels have
been documented to be increased in patients with
morphea, a localized scleroderma (10). IGF-I binds
1 of 6 different binding proteins (IGF binding protein
[IGFBP]); thus, IGFBP affects the bioactivity of IGF-I
(6,7). IGFBP-3 and -5 expressions from scleroderma
dermal fibroblasts have been reported to be increased
(11,12). IGF-I enhances the proliferation of fibroblasts
and raises the production of ECM components (13).
Similarly, IGFBP-3 and -5 exacerbate fibrotic actions
of fibroblasts in an in vitro setting (14), and IGFBP-5
induces dermal fibrosis in an in vivo experimental
model (15).
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Growth hormone (GH) induces the hepatic production
of IGF-I, while many actions of GH are orchestrated by
IGF-I (6,7). Octreotide is a somatostatin analogue that
regulates GH secretion. The expression of somatostatin
receptor subtype 2A has been shown to be increased
in patients with idiopathic pulmonary fibrosis (IPF)
(16). Subsequent studies (17–19) have demonstrated
that octreotide has antifibrotic potential on a bleomycin
(BLM)-induced pulmonary fibrosis model (17,18) and in
IPF patients (19). Therefore, in the present study, we aimed
to evaluate the prophylactic and therapeutic potentials
of octreotide on an experimental model of scleroderma
induced by BLM.
2. Materials and methods
2.1. Animals and experimental protocols
Sixty female Balb/c mice (8 weeks old, and weighing 25 to
30 g) were included in the study. The mice were divided
into 6 groups as prophylactic-early (group I [control
I], group II [sham I], and group III [octreotide I]) and
therapeutic-late (group IV [control II], group V [sham
II], and group VI [octreotide II]) groups (Figure 1). The
upper back skin was shaved for subcutaneous injections.
The study was approved by the Animal Care and Ethics
Committee of Fırat University.
Mice in groups I and IV received only phosphatebuffered saline (PBS) subcutaneously (100 µL/day)
into the shaved back skin. The remaining 4 groups
subcutaneously received 100 µg of BLM (Bleocin,
bleomycin hydrochloride; Nippon Kayaku, Tokyo, Japan)
dissolved in PBS (100 μL) to induce dermal fibrosis (20).
BLM was injected into the shaved upper back skin for 3
weeks in groups II and III and for 6 weeks in groups V and
VI. In addition to BLM, octreotide (100 µg/kg per day) was
injected subcutaneously to the dorsal front of the neck for
the first 3 weeks in group III (prophylactic) and during the
second 3 weeks in group VI (therapeutic) (21).

Figure 1. The schemes of experimental applications in the study
groups.
Cntrl: control; Oct: octreotide; PBS: phosphate buffered saline;
BLM: bleomycin.

Mice in groups I, II, and III were sacrificed at the end
of the third week, while mice in groups IV, V, and VI
were sacrificed at the end of the sixth week. After final
experimental applications, the animals were sacrificed
by cervical dislocation under anesthesia with ketamine
hydrochloride, and the back skins were collected for further
examination. The harvested skin samples were divided into
2 parts. One part was fixed with 10% formalin solution,
embedded in paraffin, and used for histopathological
examinations, and the other part was stored immediately
at –80 °C for real-time PCR (RT-PCR) analysis.
2.2. Histopathological examinations
The skin specimens that were embedded in paraffin were
sectioned using a microtome. Subsequently, the skin
specimens were stained with hematoxylin and eosin (H&E)
and Masson’s trichrome (MT). Dermal thickness was
measured from the dermal–fat junction to the epidermal–
dermal junction, and was determined from 5 randomly
selected sites of 2 or more skin sections for each animal,
at 40×, 100×, and 200× magnifications. Histopathological
examinations were performed under a light microscope
(Olympus BX-50).
2.3. Real-time RT-PCR analysis
Total RNA was isolated from skin tissue using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA). cDNAs were
generated by reverse-transcription of total RNA using a
cDNA synthesis kit (Invitrogen, Carlsbad, CA, USA). PCR
reactions were prepared in triplicate, and heated to 50 °C
for 2 min, followed by 40 cycles of denaturation at 95 °C
for 10 min, 95 °C for 15 s, and 60 °C for 1 min. Standard
curves were prepared for each target gene (Applied
Biosystems, Foster City, CA, USA) as the endogenous
reference in each sample. A real-time PCR analysis was
performed with the ABI Prism 7500 Fast Real Time PCR
Instrument (Applied Biosystems), using Tag Man Master
Mix (Applied Biosystems). The results were standardized
to the levels of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). The samples were quantified for TGF-β,
IGFBP-3, and IGFBP-5 mRNA (Applied Biosystems)
using the comparative delta Ct, as described in the user’s
manual (Applied Biosystems, Foster City, CA, USA).
2.4. Statistical analysis
Statistical evaluations were performed using IBM-SPSS-22
(Chicago, IL, USA). The data were expressed as mean ±
standard deviation. Kruskal–Wallis one-way analysis of
variance and post-hoc Mann–Whitney U test were applied
for statistical comparisons. A P value of <0.05 was accepted
to be significant.
3. Results
Repeated BLM applications led to skin fibrosis beginning
at week 3 (Figures 2 and 3). Among the prophylactic
application groups, the mean dermal inflammatory cell
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Figure 2. Dermal inflammatory cell counts (A) and dermal thicknesses (B) in the study groups.
Oct: octreotide; HPF: high power field.

Figure 3. Histopathological appearances of skin sections (H&E, 200×).
Histopathological appearance was normal in the control groups (A and D). Bleomycin caused thickened collagen bundles in dermis and
definite skin fibrosis in the sham groups (B and E). Prophylactic and therapeutic applications of octreotide ameliorated dermal fibrosis
and decreased infiltrations of inflammatory cells (C and F, respectively).

counts (31.3 ± 12.7 vs. 5.7 ± 1.9, P = 0.003) (Figure 2A)
and the mean dermal thickness (342.6 ± 47.3 vs. 197.2 ±
32.5 µm, P = 0.003) (Figure 2B) were higher in the Sham
I group when compared to the Control I group. At week
6, the mean inflammatory cell count (17.4 ± 6.8 vs. 4.7
± 2.3, P = 0.001) and dermal thickness (524.7 ± 116.9
vs. 152.5 ± 21.8 µm, P < 0.001) were higher in the Sham
II group compared to the Control II group (Figure 2).
Moreover, when compared to the own control group, the
BLM injection increased mRNA expressions of TGF-β1,
IGFBP3, and IGFBP5 133-, 3.5-, and 29-fold respectively
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at the third week and 969-, 44-, and 31-fold respectively at
the sixth week (Figure 4).
In the prophylactic octreotide group, the mean
inflammatory cell count (31.3 ± 12.7 vs. 10.6 ± 6.9,
P = 0.006) and the mean dermal thickness (342.6 ±
47.3 vs. 271.5 ± 34.4 µm, P = 0.008) were decreased
when compared to the Sham I group (Figures 2 and 3).
Moreover, therapeutic octreotide applications decreased
the mean inflammatory cell count (17.4 ± 6.8 vs. 9.3 ± 4.2,
P = 0.007) and dermal thickness (524.7 ± 116.9 vs. 253.8 ±
67.9 µm, P = 0.001) when compared to the Sham II group
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Figure 4. Dermal tissue mRNA expressions of TGFβ1 (A), IGFBP3 (B), and IGFBP5 (C).
Results are expressed as mean ± SD. The gene values were normalized to the GAPDH level.
Cntrl: control; Oct: octreotide; TGF: transforming growth factor; IGFBP: insulin-like growth factor binding protein.
*P value was <0.05 when compared to the Cntrl group.
‡
P value was <0.05 when compared to the Sham group.

(Figure 2). On the other hand, prophylactic octreotide
application decreased IGFBP-3 and -5 mRNA expressions
but not TGF-β1 mRNA expression. However, therapeutic
applications decreased TGF-β1, IGFBP-3, and IGFBP-5
mRNA expressions (Figure 4).
4. Discussion
The findings of early and late skin fibrosis in an
experimental model induced by BLM, and the prophylactic
and therapeutic potentials of octreotide on skin fibrosis
were investigated in the present study. Repeated BLM
applications led to dermal fibrosis starting at week 3,
and dermal fibrosis was marked at week 6. On the other
hand, our study showed that octreotide prevented dermal
fibrosis and ameliorated established fibrosis.
Scleroderma is characterized by skin fibrosis.
However, its pathogenesis needs to be clarified. The BLMinduced dermal fibrosis model is one of the experimental
scleroderma models. In our study, repeated BLM
injections led to dermal fibrosis and increased IGFBP-3
and -5 mRNA expressions. On the other hand, octreotide
treatment ameliorated dermal fibrosis as well as decreased
IGFBP-3 and -5 mRNA expression. These results suggest
that the IGF–IGFBP axis has a role in the pathogenesis of
dermal fibrosis.
It has been reported that IGF-I levels in sera (8) and
bronchoalveolar fluids (9) harvested from patients with
SSc are increased. Serum and dermal tissue IGF-I levels
have been documented to be increased in patients with
morphea (10). Moreover, dermal tissue IGF-I level has
been positively correlated with Rodnan skin score (10).
The IGF axis includes IGF (I and II), receptors (type
1 and 2), and IGFBP (IGFBP-1 to -6) (22). Almost all
IGF-I are in the IGFBP-bound form in the circulation.
For instance, more than 90% of the circulating IGF-I

binds IGFBP-3 (23). IGFBP-3, and -5 expressions from
scleroderma dermal fibroblasts have been reported
to be increased (11,12,24). Similarly, IGFBP-3 and -5
exacerbate fibrotic actions of fibroblasts in an in vitro
setting (14), and IGFBP-5 induces dermal fibrosis in the
in vivo experimental models (15,24). In patients with
SSc, IGFBP-5 mRNA expression is shown to be higher
in dermal fibroblasts harvested from affected skin than
in fibroblasts harvested from unaffected skin and healthy
controls (11). In patients with IPF, bronchoalveolar lavage
fluid IGFBP-3 level is documented to be increased (23). In
vitro lung fibroblast culture harvested from patients with
IPF is reported to produce higher IGFBP-3 and -5 (14).
In our study, in addition to dermal fibrosis, BLM
injections increased dermal tissue mRNA expressions
of IGFBP-3 and -5. These results suggest the pathogenic
role of the IGF–IGFBP axis on dermal fibrosis. It has been
shown that IGF-I enhances the proliferation of fibroblasts
and raises the production of ECM components (13).
Moreover, it has been reported that IGF-I enhances the
proliferation of fibroblasts and aggravates the expression
of pro-collogene-1 mRNA (25).
It is known that IGF-I is mainly produced by the liver.
However, it has been shown that it is also expressed by
dermal fibroblasts (26). Fawzi et al. (10) have demonstrated
that IGF-I level is higher in affected skin tissue than in
unaffected sites in patients with localized scleroderma. It
can be concluded that the source of IGF-I is fibroblasts in
dermal fibrosis.
In our study, octreotide prevented and ameliorated
dermal necro-inflammation and dermal fibrosis in a BLMinduced experimental scleroderma model. Octreotide,
an analogue of somatostatin, depresses the IGF-I level.
It is not uncommonly used in the treatment of several
neuroendocrine tumors and upper gastrointestinal
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bleeding. On the other hand, it has been reported that
intralesional octreotide injections improve pretibial
myxedema due to Graves’ disease (27). A subsequent
study has demonstrated that octreotide leads to regression
in the sclerodermatous skin lesions of carcinoid syndrome
(28). Moreover, the antifibrotic potential of octreotide on
both BLM-induced pulmonary fibrosis (17,18) and IPF
patients (19) has been demonstrated in previous studies.
These studies (17–18,27,28) suggest the antifibrotic effect
of octreotide.
In our study, the fibrosis and mRNA levels of TGF-β1
are more prominent in week 6 compared to week 3.
However, there was no significant difference between
prophylactic and therapeutic octreotide applications in
terms of antifibrotic potential.

The present study has several limitations. The first is
that the hypothesis of study should also be investigated in
an in vitro setting. Secondly, serum levels of GH and IGF-I
should be analyzed.
The present study documents that octreotide has
antifibrotic actions on experimentally induced dermal
fibrosis. It can be suggested that IGF-I plays a pathogenic
role, and that octreotide is a candidate for research in the
treatment of scleroderma.
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